BioCentury
ARTICLE | Clinical News

Xeplion paliperidone palmitate regulatory update

July 18, 2011 7:00 AM UTC

The Scottish Medicines Consortium recommended against Xeplion paliperidone palmitate from Johnson & Johnson on the National Health Service (NHS) in Scotland for maintenance treatment of schizophrenia ...